Market access - ensuring that patients receive the correct therapies at the desired time and best price - hinges on a seamless, compliant partner ecosystem and has become a pivotal driver of product success. Full-line wholesalers, specialty distributors, third-party logistics organizations (3PLs), pharmacy benefit managers (PBMs), group purchasing organizations (GPOs), and specialty pharmacies, are vital to delivering therapies efficiently and meeting payer expectations.

To ensure transparency and adherence to regulatory standards, companies must conduct Fair Market Value (FMV) assessments when compensating the channel partners. These FMV assessments have acquired critical strategic importance and are essential tools for optimizing market access, ensuring regulatory compliance, supporting sustainable business models, and enabling profitability through compliant and efficient partnerships. FMV assessments are thus an anchor for compliant partnerships that sustain critical market access functions like payer negotiations, patient assistance, and distribution efficiency and reliability.

How does FMV strategically shape market access?

Market access encompasses pricing, reimbursement, distribution, and patient support, all of which are influenced by the relationships manufacturers have with the channel partners. FMV assessments are needed to ensure that payments to these partners are justified, transparent, and aligned with regulatory requirements while also enabling business objectives.

What's driving healthcare's regulatory evolution?

In a challenging regulatory landscape in the United States, the Anti-Kickback Statute (AKS), Stark Law, and government pricing regulations dictate how manufacturers interact with channel partners. Globally, anti-corruption laws such as the UK Bribery Act and the Foreign Corrupt Practices Act (FCPA) impart additional complexity.

The diversity of channel partners and FMV challenges

The pharmaceutical supply chain is highly diverse, with each type of channel partner bringing unique value—and unique challenges—to FMV assessment.

• Full-line wholesalers and 3PLs are primarily responsible for logistics and distribution.
• Specialty distributors often handle limited distribution drugs and require customized FMV approaches to reflect restricted access and specialized handling.
• PBMs and GPOs play a critical role in formulary management, contract negotiation, and data analytics.
• Specialty pharmacies and hubs provide patient support, adherence programs, and specialty logistics.

FMV as a Market Access enabler, is essential for several reasons:

• Enhancing and optimizing channel strategy
• Establishing and ensuring regulatory compliance while enabling profitability
• Facilitating and supporting sustainable pricing
• Augmenting transparency and trust

How will digital and AI transform FMV assessments?

Going forward, the integration of digital health, AI-driven analytics, and centralized compliance platforms (such as IQVIA’s CPNavigator) will further transform FMV assessments. There is a need to remain agile and continuously update FMV frameworks to reflect regulatory changes and evolving service models along with market shifts.

How do FMV assessments drive pharma market access?

FMV assessments for channel partners have shifted from routine compliance checks to a strategic lever for unlocking market access in the pharmaceutical landscape. By embedding regulatory precision, technological agility, and cross-functional synergy into FMV methodologies, manufacturers can manage complexity, optimize distribution channels, and accelerate the delivery of breakthrough therapies, both compliantly and efficiently.

Leading organizations now view FMV assessments as a strategic catalyst — fostering trust with regulators, payers, and patients while fueling sustainable growth amid an increasingly complex and tightly regulated landscape.